The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

AC1NUNYN     (2S)-2-[[(2S)-2-[[(2S)-2-[2- [[(2R)-2...

Synonyms: LS-21621, Tyr-Ala-Gly-Phe-Leu-Arg, 2-Ala-6-Arg-Leu-enkephalin, Leu-enkephalin, Ala(2)-Arg(6)-, enkephalin, Ala(2)-Leu(5)-Arg(6)-, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Dalargin


High impact information on Dalargin

  • 4. Dalarginamide was more potent and selective for mu-opioid receptors than dalargin, whilst dalarginethylamide, though equipotent to dalarginamide in the myenteric plexus, was more potent at delta-opioid receptors (KB=5.0 nM) [5].
  • 3. [Met5]-dalargin was equipotent to dalargin in the myenteric plexus, but was more potent in the vasa deferentia of hamster and mouse (KB=5.5 nM) [5].
  • Leu5 and the interdependence of Leu5 and D-Ala2 are of importance for the selectivity of dalargin for mu-opioid receptors [5].
  • Selected analogues and fragments of enkephalins and dalargin were successfully separated by CZE in acidic isoelectric buffers, 100 and 200 mM iminodiacetic acid, pH 2.30 and 2.32, respectively [6].
  • Only dalargin preadsorbed to PBCA nanoparticles was able to induce an antinociceptive effect in the animals [7].

Biological context of Dalargin


Anatomical context of Dalargin


Associations of Dalargin with other chemical compounds


Gene context of Dalargin

  • Poly(butyl cyanoacrylate) nanoparticles loaded with the hexapeptide dalargin were coated with the apolipoproteins AII, B, CII, E, or J without or after precoating with polysorbate 80 [11].
  • We studied antiarrhythmic action of D-Ala 2, Leu 5, Arg 6-enkephalin (dalargin) in experiments on male rats [1].
  • The data strongly suggest that cGMP content increase and somatostatin level decrease in cardiac muscle play a significant role in antiarrhythmic action of dalargin [1].

Analytical, diagnostic and therapeutic context of Dalargin

  • We show by in situ brain perfusion that vectorization markedly enhances the brain uptake of dalargin [13].
  • Activity profiles of dalargin and its analogues in mu-, delta- and kappa-opioid receptor selective bioassays [5].
  • Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration [14].
  • Results from the tail flick test indicated that significant dalargin-induced analgesia was observed from PBCA-NDSs with double-coating of Tween and PEG in comparison with single-coating of either Tween or PEG [14].
  • Dalargin adsorption was assessed by HPLC [15].


  1. The anti-arrhythmic effect of D-Ala 2, Leu 5, Arg 6-enkephalin and its possible mechanism. Maslov, L.N., Lishmanov, Y.B. International journal of cardiology. (1993) [Pubmed]
  2. Oxidative modification of plasma proteins during hypothermia and after dalargin administration. Klichkhanov, N.K., Ismailova, Z.G., Emirbekov, E.Z. Bull. Exp. Biol. Med. (2001) [Pubmed]
  3. Misoprostol and dalargin for the inpatient treatment of duodenal ulcer in the USSR. Dajani, E.Z., Penin, V.A., Sokolov, L.K., Vahtangishvilli, R., Bogdanov, A., Afonskaya, N., Ivanishvilli, L., Zharova, Y., Efremova, I. Journal of the Association for Academic Minority Physicians : the official publication of the Association for Academic Minority Physicians. (1991) [Pubmed]
  4. Chronotropic effect of D-Ala2,Leu5,Arg6-enkephalin (dalargin) is associated with activation of peripheral kappa-opioid receptors. Maslov, L.N., Barzakh, E.I., Platonov, A.A., Minin, S.M., Ovchinnikov, M.V. Bull. Exp. Biol. Med. (2005) [Pubmed]
  5. Activity profiles of dalargin and its analogues in mu-, delta- and kappa-opioid receptor selective bioassays. Pencheva, N., Pospisek, J., Hauzerova, L., Barth, T., Milanov, P. Br. J. Pharmacol. (1999) [Pubmed]
  6. Analysis and separation of enkephalin and dalargin analogues and fragments by capillary zone electrophoresis. Solínová, V., Kasicka, V., Barth, T., Hauzerová, L., Fanali, S. Journal of chromatography. A. (2005) [Pubmed]
  7. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Kreuter, J., Ramge, P., Petrov, V., Hamm, S., Gelperina, S.E., Engelhardt, B., Alyautdin, R., von Briesen, H., Begley, D.J. Pharm. Res. (2003) [Pubmed]
  8. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Kreuter, J., Alyautdin, R.N., Kharkevich, D.A., Ivanov, A.A. Brain Res. (1995) [Pubmed]
  9. Stimulatory effect of opioid peptides and naloxone on rat spinal cord cells in primary dissociated culture. Kozlova, M., Kalentchuk, V. Int. J. Dev. Neurosci. (1994) [Pubmed]
  10. Effects of central opiate and serotoninergic structures on heart rhythm during acute myocardial ischemia. Prokop'eva, E.V., Pivovarov, Y.I. Bull. Exp. Biol. Med. (2001) [Pubmed]
  11. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. Kreuter, J., Shamenkov, D., Petrov, V., Ramge, P., Cychutek, K., Koch-Brandt, C., Alyautdin, R. Journal of drug targeting. (2002) [Pubmed]
  12. Body distribution of 3H-labelled dalargin bound to poly(butyl cyanoacrylate) nanoparticles after i.v. injections to mice. Schroeder, U., Schroeder, H., Sabel, B.A. Life Sci. (2000) [Pubmed]
  13. Improved brain uptake and pharmacological activity of dalargin using a peptide-vector-mediated strategy. Rousselle, C., Clair, P., Smirnova, M., Kolesnikov, Y., Pasternak, G.W., Gac-Breton, S., Rees, A.R., Scherrmann, J.M., Temsamani, J. J. Pharmacol. Exp. Ther. (2003) [Pubmed]
  14. Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration. Das, D., Lin, S. Journal of pharmaceutical sciences. (2005) [Pubmed]
  15. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Olivier, J.C., Fenart, L., Chauvet, R., Pariat, C., Cecchelli, R., Couet, W. Pharm. Res. (1999) [Pubmed]
WikiGenes - Universities